Bioage Labs

Bioage Labs company information, Employees & Contact Information

Explore related pages

Related company profiles:

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.

Company Details

Employees
94
Founded
-
Address
1445a S 50th St, Richmond,ca 94804,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Richmond, CA
Looking for a particular Bioage Labs employee's phone or email?

Bioage Labs Questions

News

BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewswire

BioAge Labs to Present at Upcoming Investor Conferences GlobeNewswire

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Sahm

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic Sahm

BioAge Labs Announces First Participant Dosed in Phase 1 - GlobeNewswire

BioAge Labs Announces First Participant Dosed in Phase 1 GlobeNewswire

BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging - Business Wire

BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging Business Wire

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs - GlobeNewswire

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs GlobeNewswire

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates Yahoo Finance

BioAge Labs Launches Initiative to Analyze Over 17,000 HUNT Biobank Samples for Drug Discovery in Aging-Related Diseases - Nasdaq

BioAge Labs Launches Initiative to Analyze Over 17,000 HUNT Biobank Samples for Drug Discovery in Aging-Related Diseases Nasdaq

BioAge Labs - The Pharma Letter

BioAge Labs The Pharma Letter

BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs - Business Wire

BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs Business Wire

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates Yahoo Finance

BioAge Labs, Inc. Reports Promising Preclinical Results for APJ Agonist in Enhancing Glycemic Control and Cardioprotection in Diabetic Obesity and Heart Failure - Nasdaq

BioAge Labs, Inc. Reports Promising Preclinical Results for APJ Agonist in Enhancing Glycemic Control and Cardioprotection in Diabetic Obesity and Heart Failure Nasdaq

BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer - Business Wire

BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer Business Wire

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions - Yahoo Finance

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions Yahoo Finance

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics - Business Wire

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics Business Wire

BioAge Labs Announces Discontinuation of STRIDES Phase 2 - GlobeNewswire

BioAge Labs Announces Discontinuation of STRIDES Phase 2 GlobeNewswire

BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors - Business Wire

BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors Business Wire

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization - Business Wire

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization Business Wire

BioAge Labs Announces Pricing of Upsized Initial Public Offering - GlobeNewswire

BioAge Labs Announces Pricing of Upsized Initial Public Offering GlobeNewswire

BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq

BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists Nasdaq

BioAge Labs, Inc. Advances NLRP3 Inhibitor BGE-102 and Forms Strategic Collaborations with Novartis and Lilly for Metabolic Diseases - Nasdaq

BioAge Labs, Inc. Advances NLRP3 Inhibitor BGE-102 and Forms Strategic Collaborations with Novartis and Lilly for Metabolic Diseases Nasdaq

Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO - Reuters

Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO Reuters

BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM - Business Wire

BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM Business Wire

BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest - Business Wire

BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest Business Wire

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq - Fast Company

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq Fast Company

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - Yahoo Finance

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates Yahoo Finance

BIOA Stock Price and Chart — NASDAQ:BIOA - TradingView

BIOA Stock Price and Chart — NASDAQ:BIOA TradingView

BioAge Labs to launch Phase II obesity treatment trial - Clinical Trials Arena

BioAge Labs to launch Phase II obesity treatment trial Clinical Trials Arena

BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications - Business Wire

BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications Business Wire

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October - The Motley Fool

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October The Motley Fool

Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials - MedCity News

Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials MedCity News

Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug - MedCity News

Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug MedCity News

BIOA IPO News - Obesity biotech BioAge Labs sets terms for $135 million IPO - renaissancecapital.com

BIOA IPO News - Obesity biotech BioAge Labs sets terms for $135 million IPO renaissancecapital.com

Drug Repurposing Using Deep Embeddings of Gene Expression Profiles - ACS Publications

Drug Repurposing Using Deep Embeddings of Gene Expression Profiles ACS Publications

A longevity expert who studied people who live to 110 on how humanity and AI will master aging - CNBC

A longevity expert who studied people who live to 110 on how humanity and AI will master aging CNBC

Top Bioage Labs Employees

  • "Joe Betts-LaCroix"

    Leading All Teams At Retro

    San Francisco, California, United States, United States
    8
    mousera.com, vium.com, gmail.com, healthextension.co, oqo.com, ycombinator.com, retro.bio, retro.bio

    3 +141579XXXXX

  • Chris Patil

    Chris Patil

    n/a

    San Francisco, California, United States, United States
    4
    gmail.com, mac.com, gmail.com, bioagelabs.com

    1 +141520XXXXX

  • Rekha Hemrajani

    Rekha Hemrajani

    n/a

    San Francisco Bay Area, United States
    11
    gmail.com, exelixis.com, flxbio.com, 3vbio.com, onyx.com, lehman.com, pacbell.net, jiyacorp.com, arcusbio.com, exelixis.com, flxbio.com

    11 +165055XXXXX

  • Peng Leong

    Peng Leong

    Cbo And Head Of Brain Aging | Company…

    San Francisco, California, United States, United States
    5
    mba.berkeley.edu, merckgroup.com, emdserono.com, gmail.com, bioagelabs.com

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant